Company intelligence / Profile preview
Surv BioPharma
Kagoshima, Kagoshima, Japansurvbiopharma.co.jp ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Surv.m-CRA-1, a survivin promoter-driven oncolytic virus, showed highly favorable efficacy and safety in a Phase II trial for primary malignant bone tumors in Japan; preparing to initiate Phase III in October 2025 aiming for full regulatory approval by 2027. Surv.m-CRA-2-IC is at the non-clinical stage and incorporates immunogenes for systemic anti-tumor activity[5].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Nippon Zoki Pharmaceutical (Japan, exclusive license for Surv.m-CRA-1 in bone/soft tissue tumors) [5]
Beyond the preview
Go deeper on Surv BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Surv BioPharma.